ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2012
Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study.Radiation oncology (London, England) · 2020Trial
- A density assignment method for dose monitoring in head-and-neck radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019Trial
- Single-Institute Clinical Experiences Using Whole-Field Simultaneous Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) and Sequential IMRT in Postoperative Patients With Oral Cavity Cancer (OCC).Cancer control : journal of the Moffitt Cancer CenterTrial
- Dose monitoring-guided replanning timing in adaptive radiotherapy for laryngeal cancer.Physical and engineering sciences in medicine · 2026Article
- Daily adaptive radiotherapy in head and neck squamous cell carcinoma can negatively impact organ at risk dosimetry.Clinical and translational radiation oncology · 2026Article
- Estimation of accumulated dose to organs at risk in head and neck cancer patients treated with scheduled replanning and dose painting in the ARTFORCE trial.Physics and imaging in radiation oncology · 2026Article
- Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist's point of view.Cancer medicine · 2024Review
- Impact of elective nodal irradiation ≥ 60 Gy on severe weight loss during intensity-modulated radiation therapy in patients with head and neck squamous cell carcinoma.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- Dosimetrically triggered adaptive radiotherapy for head and neck cancer: Considerations for the implementation of clinical protocols.Journal of applied clinical medical physics · 2023Article
- Adaptive Volumetric-Modulated Arc Radiation Therapy for Head and Neck Cancer: Evaluation of Benefit on Target Coverage and Sparing of Organs at Risk.Current oncology (Toronto, Ont.) · 2023Article
- Criteria for Verification and Replanning Based on the Adaptive Radiotherapy Protocol "Best for Adaptive Radiotherapy" in Head and Neck Cancer.Life (Basel, Switzerland) · 2022Article
- Adaptive proton therapy.Physics in medicine and biology · 2021Review
- Correlation between 3D scanner image and MRI for tracking volume changes in head and neck cancer patients.Journal of applied clinical medical physics · 2021Article
- Adaptive radiotherapy based on statistical process control for oropharyngeal cancer.Journal of applied clinical medical physics · 2020Article
- Article
- Adaptive radiotherapy for head and neck cancer reduces the requirement for rescans during treatment due to spinal cord dose.Radiation oncology (London, England) · 2019Article
- Head and Neck Cancer Adaptive Radiation Therapy (ART): Conceptual Considerations for the Informed Clinician.Seminars in radiation oncology · 2019Review
- CT-based dose recalculations in head and neck cancer radiotherapy: comparison of daily dose recalculations to less time-consuming approaches.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019Article
- Parotid gland radiation dose-xerostomia relationships based on actual delivered dose for nasopharyngeal carcinoma.Journal of applied clinical medical physics · 2018Article
- Potential proton and photon dose degradation in advanced head and neck cancer patients by intratherapy changes.Journal of applied clinical medical physics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe goal of the present study was to assess the frequency and impact of replanning triggered solely by soft tissue changes observed on the daily setup mega-voltage CT (MVCT) in head and neck cancer (H&N) helical tomotherapy (HT). MATERIAL AND
methodsA total of 11 patients underwent adaptive radiotherapy (ART) using MVCT. Preconditions were a soft tissue change > 0.5 cm and a tight mask. The dose–volume histograms (DVHs) derived from the initial planning kVCT (inPlan), the recalculated DVHs of the fraction (fx) when replanning was decided (actSit) and the DVHs of the new plan (adaptPlan) were compared. Assessed were the following: maximum dose (Dmax), minimum dose (Dmin), and mean dose (Dmean) to the planning target volume (PTV) normalized to the prescribed dose; the Dmean/fx to the parotid glands (PG), oral cavity (OC), and larynx (Lx); and the Dmax/fx to the spinal cord (SC) in Gy/fx.
resultsNo patient had palpable soft tissue changes. The median weight loss at the moment of replanning was 2.3 kg. The median PTV Dmean was 100% for inPlan, 103% for actSit, and 100% for adaptPlan. The PTV was always covered by the prescribed dose. A statistically significant increase was noted for all organs at risk (OAR) in the actSit. The Dmean to the Lx, the Dmean to the OC and the Dmax to the SC were statistically better in the adaptPlan. No statistically significant improvement was achieved by ART for the PGs. No significant correlations between weight and volume loss or between the volume changes of the organs to each other were observed, except a strong positive correlation of the shrinkage of the PGs (ρ = + 0.77, p = 0.005).
conclusionSoft tissue shrinkage without clinical palpable changes will not affect the coverage of the PTV, but translates into a higher delivered dose to the PTV itself and the normal tissue outside the PTV. The gain by ART in individual patients—especially in patients who receive doses close to the tolerance doses of the OAR—could be substantial.
Indexed as
Identifiers
22294198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.